AGM Details

The 39th Annual General Meeting of Bal Pharma Limited is scheduled to be held on Thursday, September 24, 2026, at 11:30 A.M. (IST) through Video Conferencing / Other Audio-Visual Means (VC/OAVM) facility. The meeting will be conducted without physical presence of members as permitted by MCA circulars.

Key Dates

  • Record Date for Final Dividend & E-voting Cut-off: Thursday, September 17, 2026
  • Book Closure Period: Friday, September 18, 2026 to Thursday, September 24, 2026 (both days inclusive)
  • E-voting Commencement: Monday, September 21, 2026 at 9:00 A.M.
  • E-voting End: Wednesday, September 23, 2026 at 5:00 P.M.
  • Dividend Payment Date: On or before October 24, 2026

Ordinary Business Agenda

1. Adoption of Financial Statements: To receive, consider, and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, together with Reports of the Board of Directors and Auditors.

2. Declaration of Dividend: To declare a final dividend of ₹1.20 per equity share (12% on face value of ₹10 each) for FY 2025-26. The dividend will be paid to members registered as of the record date of September 17, 2026, subject to TDS.

3. Re-appointment of Director: To re-appoint Mr. Ravindra Kumar Kothari (DIN: 03418320), who retires by rotation, as a Director of the Company.

Special Business Agenda

4. Ratification of Cost Auditor Remuneration: To ratify the remuneration payable to Cost Auditors, Messrs. GNV & Associates (Firm Registration No. 000150), for the Financial Year 2026-27. The remuneration approved by the Board is ₹75,000 (plus applicable taxes, excluding out-of-pocket expenses).

5. Renewal of Related Party Contract: To approve the renewal of the contract with Messrs. Desa Marketing International (a related party as it is a proprietary concern of Mr. Shailesh Siroya, Managing Director). The agreement is for vendor identification, marketing promotion, and export facilitation services. The renewal is for a term of 3 years from May 20, 2026, to May 19, 2029. Remuneration is 2% of domestic sourcing/marketing value and 3% of international value, plus taxes. The aggregate value of transactions is capped at ₹30 Crore per financial year.

6. Change in Director Designation (Special Resolution): To approve the change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non-Executive Director to Whole-Time Director (Executive category), effective from October 1, 2026, until July 30, 2030. His remuneration is set at a gross amount of ₹22,50,000 per annum for 3 years effective October 1, 2026. His office will be liable to retire by rotation.

7. Change in Director Designation (Special Resolution): To approve the change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director, effective from October 1, 2026, until July 31, 2029. He will receive an honor remuneration of ₹2,40,000 per annum instead of his previous executive remuneration. His office will be liable to retire by rotation.

Voting Information

The company is providing remote e-voting facilities through NSDL and CDSL. The remote e-voting period is from September 21, 2026 (9:00 AM) to September 23, 2026 (5:00 PM). Members can also vote during the AGM via the e-voting system if they have not voted remotely.

Other Key Disclosures

  • The Annual Report for FY 2025-26 is available on the company's website (www.balpharma.com).
  • The company has transferred ₹2,01,842 from its Unpaid Dividend Account for FY 2017-18 to the Investor Education and Protection Fund (IEPF).
  • Members are encouraged to hold shares in dematerialized form as per SEBI regulations.
  • The company has appointed Mr. Parameshwar G Bhat, Practicing Company Secretary, as the Scrutinizer for the e-voting process.
  • The results of the voting will be announced within 2 working days of the AGM and posted on the company's website.

Financial Impact

  • Dividend outflow is based on the number of shares outstanding as of the record date (not quantified in the notice).
  • The remuneration for Cost Auditors and Directors is as specified in the resolutions.
  • The related party transaction with Desa Marketing International has a monetary cap of ₹30 Crore per annum.